Scientific publications
Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT). Scientific Publication
Nicola Polverelli 1 , Katya Mauff 2 , Nicolaus Kröger 3 , Marie Robin 4 , Dietrich Beelen 5 , David Beauvais 6 , Patrice Chevallier 7 , Mohamad Mohty 8 9 10 , Jakob Passweg 11 , Marie Thérèse Rubio 12 , Johan Maertens 13 , Jürgen Finke 14 , Martin Bornhäuser 15 , Radovan Vrhovac 16 , Grzegorz Helbig 17 , Jean-Baptiste Mear 18 , Luca Castagna 19 , Péter Reményi 20 , Emanuele Angelucci 21 , Dimitrios Karakasis 22 , Jose Rifòn 23 , Tiarlan Sirait 2 , Domenico Russo 1 , Liesbeth de Wreede 24 , Tomasz Czerw 25 , Juan Carlos Hernández-Boluda 26 , Patrick Hayden 27 , Donal McLornan 28 , Ibrahim Yakoub-Agha 29
Abstract
The role of spleen size and splenectomy for the prediction of post-allogeneic hematopoietic stem cell transplant (allo-HCT) outcome in myelofibrosis remains under debate.
In EBMT registry, we identified a cohort of 1195 myelofibrosis patients transplanted between 2000-2017 after either fludarabine-busulfan or fludarabine-melphalan regimens. Overall, splenectomy was performed in 202 (16.9%) patients and its use decreased over time (28.3% in 2000-2009 vs 14.1% in 2010-2017 period). By multivariate analysis, splenectomy was associated with less NRM (HR 0.64, 95% CI 0.44-0.93, P = .018) but increased risk of relapse (HR 1.43, 95% CI 1.01-2.02, P = .042), with no significant impact on OS (HR 0.86, 95% CI 0.67-1.12, P = .274).
However, in subset analysis comparing the impact of splenectomy vs specific spleen sizes, for patients with progressive disease, an improved survival was seen in splenectomised subjects compared to those patients with a palpable spleen length ≥ 15 cm (HR 0.44, 95% CI 0.28-0.69, P < .001), caused by a significant reduction in NRM (HR 0.26, 95% CI 0.14-0.49, P < .001), without significantly increased relapse risk (HR 1.47, 95% CI 0.87-2.49, P = .147).
Overall, despite the possible biases typical of retrospective cohorts, this study highlights the potential detrimental effect of massive splenomegaly in transplant outcome and supports the role of splenectomy for myelofibrosis patients with progressive disease and large splenomegaly.
CITATION Am J Hematol. 2021 Jan;96(1):69-79. doi: 10.1002/ajh.26020. Epub 2020 Oct 27
Our authors
